Navigation Links
Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
Date:12/21/2007

CALGARY, Dec. 21 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in its Phase Ia/Ib U.K. clinical trial investigating the intratumoural delivery of REOLYSIN(R) in combination with radiation to treat patients with advanced cancers. A total of 23 patients received a range of two to six intratumoural doses of REOLYSIN(R) at escalating dosages up to a maximum of 1x10(10) TCID(50) with a constant localized radiation dose of either 20 Gy or 36 Gy. The treatment appears to have been well tolerated by the patients and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers.

Interim results were presented at the National Cancer Research Institute conference on October 2, 2007 in Birmingham, U.K. and at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on October 24, 2007.

The primary objective of the trial is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of REOLYSIN(R) when administered intratumourally to patients receiving radiation treatment. A secondary objective is to examine any evidence of anti-tumour activity. Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The principal investigators for the trial are Dr. Kevin Harrington of the Targeted Therapy Laboratory, Cancer Research UK Centre for Cell and Molecular Biology, The Institute of Cancer Research and Honorary Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust, London, UK, and Dr. Alan Melcher of the Cancer Research U.K. Clinical Centre at St. James's University Hospital in Leeds. The trial enrolled patients at the Royal Marsden and St. James's Hospitals in the U.K.

About Oncolytics Bi
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 A study has been launched ... Formula 1 track could help to tackle the problem of ... Stowhealth (a GP surgery based in Stowmarket) and academics at ... Telemetry technology, which is inspired by equipment used ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... , May 4 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ... studies with ANAVEX 2-73, the company,s lead compound for the treatment ... , , ... class of drugs that target mitochondrial dysfunction thought to be caused ...
... Packing Record Tetrahedral dice, which have four ... yet tested, according to research performed by a collaboration ... revelation is the result of a series of experiments ... and adding more dice until the containers were completely ...
... , , , ... EDMONTON, AB , May 3 /PRNewswire-FirstCall/ - ... strategy. The Company,s new strategy will encompass becoming a full ... invest in and advise companies on strategy, financing, mergers & ...
Cached Biology Technology:Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 3Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 4Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 5Densest dice packing and computing with molecules 2BioMS updates corporate strategy and adds leading healthcare investment banker 2BioMS updates corporate strategy and adds leading healthcare investment banker 3
(Date:4/16/2014)... eyes up, and you cannot lift your upper eyelid. You walk ... look straight when they are rolled down in the eye socket. ... normal position of their head. In order to correct this condition, ... paper published in the April 16 print issue of the journal ...
(Date:4/16/2014)... Biosciences Division of Lawrence Berkeley National Laboratory (Berkeley Lab) ... authority on the evolutionary design principles of cellular networks ... biology, has been named one of six recipients of ... Secretary Ernest Moniz. The E.O. Lawrence Award, the Department ...
(Date:4/16/2014)... Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of ... Freiburg have discovered the receptor responsible for smuggling the toxin ... The TpeL toxin, which is formed by C. perfringens ... It is very similar to the toxins of many other ...
Breaking Biology News(10 mins):Researchers track down cause of eye mobility disorder 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3Gate for bacterial toxins found 2
... July 6 Delays in cargo screening significantly extend ... be shortened with foolproof and rapid screening and detection ... smuggling augment the need for efficient access control systems ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , New analysis from ...
... , WASHINGTON, July 7 Eight supply chain professionals were ... organization,s Board of Directors, joining the seven existing members of SCC,s board. ... through June 30, 2012, are as follows: , , , ... CTO, Manufacturing & Distribution Industries, Hewlett Packard , ...
... , , LONDON, July 10 IBM (NYSE: ... executive agency of the UK Home Office, have signed a seven-year agreement ... upgrade to biometric passports and enhance the security of the UK border. ... (UKBA) Immigration and Asylum Fingerprint System (IAFS) which holds biometrics collected from ...
Cached Biology News:Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 2Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 3UK Identity and Passport Service and IBM Sign 7-year National Biometric Identity Service (NBIS) Contract 2
... culture or fermentation is the ability to ... make rapid adjustments in response to changes ... provide immediate analysis of key nutrients, metabolites, ... media. BioProfile analyzers are fully automated, multi-test ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
... sequence corresponds to residues 115-133 of rat SAP97. The sequence ... L - P - S - E - R - I ... N - E - V - L - G - P ... conjugation and is not a part of the native rat SAP97 ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
Biology Products: